Novozymes and Syngenta strike a deal under which Syngenta will market and sell Novozyme’s biofungicide product Taegro.
Financial terms of the deal, which was announced Friday, were not disclosed.
Taegro targets fungal diseases in various crops.
“This collaboration matches Syngenta’s global market strength and leading position within fungicides and integrated solutions with Novozymes’ deep know-how on sustainable, biobased technologies,” said Thomas Videbæk, executive vice president of Novozymes. “Using technology developed by Novozymes, Syngenta will provide farmers all over the world with a biological product to help sustainably combat fungal diseases in a powerful manner.”
Novozymes operates its North American headquarters in Franlkinton.
Syngenta maintains its North American headquarters in RTP.
